Chai Shots #005: Miscalibrated Lipids

Why PCSK9 Inhibitor May Not Work for South Asians and Lp(a)

If you’ve been following lipid management guidelines, you’ve probably heard about PCSK9 inhibitors, the “miracle drugs” that cut LDL-C by 50-60%. Repatha, Praluent, and the newer siRNA agent inclisiran have transformed cardiovascular prevention.

So here’s the uncomfortable question to ask: What if this entire therapeutic strategy was optimized for the wr…